Combination of Cystatins 9 and C Modulates Serum Biomarkers Associated with Inflammation and Provides Prophylactic as Well as Long-Term Protection against Multidrug-ResistantKlebsiella pneumoniae | Zendy

Alex J. Holloway | Zendy; JiehJuen Yu | Zendy; Bernard P. Arulanandam | Zendy; Gregg N. Milligan | Zendy; Tonyia EavesPyles | Zendy

Open Access

Combination of Cystatins 9 and C Modulates Serum Biomarkers Associated with Inflammation and Provides Prophylactic as Well as Long-Term Protection against Multidrug-ResistantKlebsiella pneumoniae

Author(s) -

Alex J. Holloway,

JiehJuen Yu,

Bernard P. Arulanandam,

Gregg N. Milligan,

Tonyia EavesPyles

Publication year - 2019

Publication title -

antimicrobial agents and chemotherapy

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 2.07

H-Index - 259

eISSN - 1070-6283

pISSN - 0066-4804

DOI - 10.1128/aac.02519-18

Subject(s) - klebsiella pneumoniae , multiple drug resistance , pneumonia , klebsiella pneumonia , microbiology and biotechnology , klebsiella , enterobacteriaceae , biology , medicine , antibiotics , pseudomonas aeruginosa , bacteria , escherichia coli , gene , biochemistry , genetics

We have identified recombinant human cystatins 9 (rCST9) and C (rCSTC) as a combination immunotherapeutic treatment against multidrug-resistant (MDR) New Delhi metallo-β-lactamase-1 (NDM-1)-producing Klebsiella pneumoniae We evaluated the lasting protection of rCST9/rCSTC treatment against MDR NDM-1 K. pneumoniae pneumonia. Results showed that rCST9/rCSTC treatment modulated endogenous serum biomarkers, cystatins 9 and C and amyloid A, associated with poor patient outcomes and provided prophylactic and long-term protection in a murine model of pneumonia.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research